Alembic Pharmaceuticals announced on Thursday that its US subsidiary, Alembic Pharmaceuticals, Inc., has acquired UK-based Utility Therapeutics Ltd in a deal valued at $12 million (over ₹100 crore). The acquisition marks a strategic move to strengthen Alembic’s footprint in the United States pharmaceutical market.
With this acquisition, Alembic will now commercialize Utility Therapeutics’ FDA-approved product Pivya (pivmecillinam), which is indicated for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women. The US FDA granted approval for Pivya in April 2024.
“This acquisition marks our entry into the specialty and branded prescription segment, giving us access to the US branded pharmaceuticals market,” said Pranav Amin, Managing Director of Alembic Pharmaceuticals. “With Pivya, we are poised for a near-term commercial launch and are excited about the growth opportunities this creates.”
Tom Hadley, President and CEO of Utility Therapeutics, added, “Alembic Pharmaceuticals recognizes the clinical importance and market potential of Pivya. We are confident that their capabilities will ensure this much-needed treatment reaches women across the US.”
Alembic noted that the acquisition allows its US arm to expand beyond generic drugs into the branded therapeutic segment. The company plans to launch Pivya commercially in the US in the fourth quarter of 2025.